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Erug Therapy for
ypercholesterolemia
ime to End the Double Standard
n his Viewpoint paper regarding atherosclerosis screening, Shah (1)
ecries the “double standard” of requiring proof of clinical benefit for
maging studies but not for clinical risk scores. However, a far more
roublesome double standard relates to the treatment of hypercholes-
erolemia versus the treatment of other modifiable cardiovascular risk
actors. The initiation of drug therapy for hypertension, diabetes, and
igarette smoking is not dependent on any calculation of the estimated
isk of developing a hard cardiovascular end point within an arbitrary
ime period. Those with hypertension or diabetes who do not reach
heir treatment goals with lifestyle modification alone or those who
re unable to quit smoking “cold turkey” are appropriately treated with
rug therapy. In fact, the Seventh Report of the Joint National
ommittee on Prevention, Detection, Evaluation, and Treatment of
igh Blood Pressure (JNC 7) explicitly states that it “does not stratify
ypertensive individuals by the presence or absence of risk factors
. . . in order to make different treatment recommendations . . . . JNC
suggests that all people with hypertension . . . be treated” (2).
mong the modifiable cardiovascular risk factors, only hypercholes-
erolemia requires anything other than the presence of the risk factor
tself to prompt treatment.
Shah (1) explicitly raises this issue himself, but dismisses the
nconditional treatment of hypercholesterolemia with statins because
f concerns regarding cost, need for lifetime use, and intolerance.
owever, these concerns are certainly no different than those associ-
ted with drug treatment for hypertension or diabetes, issues not
ddressed by Shah (1). Moreover, statins are among the safest
edications ever introduced (3) and are generally no more expensive
r risky than many widely prescribed antihypertensive and antidiabetic
rugs. Most remarkably, Shah (1) is not in favor of unconditional
reatment of hypercholesterolemia, in part because statin therapy
only addresses about 30% to 50% of the risk.” It is difficult to
nderstand why a reduction of risk of this magnitude for a condition
hat accounts for nearly one-third of all deaths worldwide would
epresent anything other than a powerful endorsement of treatment. It
s time to embrace the unconditional treatment of hypercholesterol-
mia and bring lipid treatment in line with the well-established
reatment paradigms for other cardiovascular risk factors.
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appreciate the comments by Dr. Cooper regarding my Viewpoint
aper (1). I fully concur with Dr. Cooper that 30% to 50% relative
ardiovascular risk reduction with statins is a highly clinically worth-
hile benefit, but I beg to differ that unconditional treatment of
veryone without known atherothrombotic cardiovascular disease and
yperlipidemia with a statin is appropriate. It is an established fact
hat atherothrombotic cardiovascular disease does not develop in a
ignificant proportion of subjects with hyperlipidemia, and, con-
ersely, a significant proportion of subjects with atherothrombotic
ardiovascular disease do not have hyperlipidemia; in fact, the real
efinition of what constitutes hyperlipidemia is itself unclear. If the
oal of using a statin is to reduce atherothrombotic cardiovascular
vents, then it is unrealistic to expect those patients without significant
therosclerosis to benefit from statin therapy even if they have
yperlipidemia; in such subjects, one can only expect side effects and
xtra costs associated with statin use. Fortunately, we now have the
bility to identify subclinical atherosclerosis in 2 major vascular beds
oninvasively so that those patients without atherosclerosis can be
bserved and reassessed while adopting a healthy lifestyle without
esorting to statin therapy. Because hypertension has adverse effects
eyond simply an association with atherosclerosis, such as increased
isk of stroke, especially hemorrhagic stroke, renal failure, congestive
eart failure, and aortic aneurysm formation, one cannot equate
yperlipidemia management with hypertension management. Simi-
arly, smoking-associated health risk includes lung disease, cancer, and
hrombotic cardiovascular events even with minimal atherosclerosis;
moking cessation is advisable for every smoker regardless of other risk
actors. In this day and age, where we are headed toward the concept
f “personalized medicine” (matching treatment to underlying risk
nd disease phenotype rather than a “one size fits all” strategy, which
as been the prevailing paradigm), the approach outlined in my
iewpoint paper is a step in that direction.
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